136 related articles for article (PubMed ID: 34270257)
1. Discovery of 1-Benzoyl 4-Phenoxypiperidines as Small-Molecule Inhibitors of the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
Li Z; Zhang M; Teuscher KB; Ji H
J Med Chem; 2021 Aug; 64(15):11195-11218. PubMed ID: 34270257
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 2-(3-(3-Carbamoylpiperidin-1-yl)phenoxy)acetic Acid Derivatives as Novel Small-Molecule Inhibitors of the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
Wang Z; Zhang M; Luo W; Zhang Y; Ji H
J Med Chem; 2021 May; 64(9):5886-5904. PubMed ID: 33902288
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Selective Small-Molecule Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction through the Optimization of the Acyl Hydrazone Moiety.
Catrow JL; Zhang Y; Zhang M; Ji H
J Med Chem; 2015 Jun; 58(11):4678-92. PubMed ID: 25985283
[TBL] [Abstract][Full Text] [Related]
4. Rational design of selective small-molecule inhibitors for β-catenin/B-cell lymphoma 9 protein-protein interactions.
Hoggard LR; Zhang Y; Zhang M; Panic V; Wisniewski JA; Ji H
J Am Chem Soc; 2015 Sep; 137(38):12249-60. PubMed ID: 26352795
[TBL] [Abstract][Full Text] [Related]
5. Structure-Based Optimization of Small-Molecule Inhibitors for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
Zhang M; Wang Z; Zhang Y; Guo W; Ji H
J Med Chem; 2018 Apr; 61(7):2989-3007. PubMed ID: 29566337
[TBL] [Abstract][Full Text] [Related]
6. Discovery of an Orally Bioavailable Small-Molecule Inhibitor for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
Wang Z; Zhang M; Quereda V; Frydman SM; Ming Q; Luca VC; Duckett DR; Ji H
J Med Chem; 2021 Aug; 64(16):12109-12131. PubMed ID: 34382808
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in β-catenin/BCL9 protein-protein interaction inhibitors.
Zhang H; Bao Y; Liu C; Li J; Zhu D; Zhang Q
Future Med Chem; 2021 May; 13(10):927-940. PubMed ID: 33849283
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of β-catenin/B cell lymphoma 9 protein-protein interaction using α-helix-mimicking sulfono-γ-AApeptide inhibitors.
Sang P; Zhang M; Shi Y; Li C; Abdulkadir S; Li Q; Ji H; Cai J
Proc Natl Acad Sci U S A; 2019 May; 116(22):10757-10762. PubMed ID: 31088961
[TBL] [Abstract][Full Text] [Related]
9. New ZW4864 Derivatives as Small-Molecule Inhibitors for the β-Catenin/BCL9 Protein-Protein Interaction.
Wang Z; Zhang M; Thompson HM; Ji H
ACS Med Chem Lett; 2022 May; 13(5):865-870. PubMed ID: 35586435
[TBL] [Abstract][Full Text] [Related]
10. Rational design of small-molecule inhibitors for β-catenin/T-cell factor protein-protein interactions by bioisostere replacement.
Yu B; Huang Z; Zhang M; Dillard DR; Ji H
ACS Chem Biol; 2013 Mar; 8(3):524-9. PubMed ID: 23272635
[TBL] [Abstract][Full Text] [Related]
11. Optimization of Peptidomimetics as Selective Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction.
Wang Z; Zhang M; Wang J; Ji H
J Med Chem; 2019 Apr; 62(7):3617-3635. PubMed ID: 30856332
[TBL] [Abstract][Full Text] [Related]
12. AlphaScreen selectivity assay for β-catenin/B-cell lymphoma 9 inhibitors.
Zhang M; Wisniewski JA; Ji H
Anal Biochem; 2015 Jan; 469():43-53. PubMed ID: 25312469
[TBL] [Abstract][Full Text] [Related]
13. Structure-Based Design of 1,4-Dibenzoylpiperazines as β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction Inhibitors.
Wisniewski JA; Yin J; Teuscher KB; Zhang M; Ji H
ACS Med Chem Lett; 2016 May; 7(5):508-13. PubMed ID: 27190602
[TBL] [Abstract][Full Text] [Related]
14. Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling.
Takada K; Zhu D; Bird GH; Sukhdeo K; Zhao JJ; Mani M; Lemieux M; Carrasco DE; Ryan J; Horst D; Fulciniti M; Munshi NC; Xu W; Kung AL; Shivdasani RA; Walensky LD; Carrasco DR
Sci Transl Med; 2012 Aug; 4(148):148ra117. PubMed ID: 22914623
[TBL] [Abstract][Full Text] [Related]
15. Small molecule modulators of Wnt/β-catenin signaling.
Mook RA; Chen M; Lu J; Barak LS; Lyerly HK; Chen W
Bioorg Med Chem Lett; 2013 Apr; 23(7):2187-91. PubMed ID: 23453073
[TBL] [Abstract][Full Text] [Related]
16. SOX7 Suppresses Wnt Signaling by Disrupting β-Catenin/BCL9 Interaction.
Fan R; He H; Yao W; Zhu Y; Zhou X; Gui M; Lu J; Xi H; Deng Z; Fan M
DNA Cell Biol; 2018 Feb; 37(2):126-132. PubMed ID: 29271667
[TBL] [Abstract][Full Text] [Related]
17. Getting a Grip on the Undrugged: Targeting β-Catenin with Fragment-Based Methods.
Kessler D; Mayer M; Zahn SK; Zeeb M; Wöhrle S; Bergner A; Bruchhaus J; Ciftci T; Dahmann G; Dettling M; Döbel S; Fuchs JE; Geist L; Hela W; Kofink C; Kousek R; Moser F; Puchner T; Rumpel K; Scharnweber M; Werni P; Wolkerstorfer B; Breitsprecher D; Baaske P; Pearson M; McConnell DB; Böttcher J
ChemMedChem; 2021 May; 16(9):1420-1424. PubMed ID: 33275320
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the interaction of BCL9 with beta-catenin and development of fluorescence polarization and surface plasmon resonance binding assays for this interaction.
Kawamoto SA; Thompson AD; Coleska A; Nikolovska-Coleska Z; Yi H; Wang S
Biochemistry; 2009 Oct; 48(40):9534-41. PubMed ID: 19715304
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Novel 3-Phenylpiperidine Derivatives Targeting the β-Catenin/B-Cell Lymphoma 9 Interaction as a Single Agent and in Combination with the Anti-PD-1 Antibody for the Treatment of Colorectal Cancer.
Zhang H; Liu C; Chen Q; Shen LA; Xiao W; Li J; Wang Y; Zhu D; Zhang Q; Li J
J Med Chem; 2023 Jan; 66(2):1349-1379. PubMed ID: 36630177
[TBL] [Abstract][Full Text] [Related]
20. The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the β-Catenin Coactivator BCL9-2 in Breast Cancer Cells.
El-Hage P; Petitalot A; Monsoro-Burq AH; Maczkowiak F; Driouch K; Formstecher E; Camonis J; Sabbah M; Bièche I; Lidereau R; Lallemand F
Mol Cancer Res; 2015 May; 13(5):902-12. PubMed ID: 25678599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
